Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

The conversation is about alternative measures for hair regrowth for those who did not respond to finasteride or dutasteride, including the use of minoxidil and addressing vitamin deficiencies through blood tests.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

The conversation is about using 1mg finasteride and 5% topical minoxidil for hair loss, along with a dermaroller, Alpecin caffeine shampoo, and Nizoral shampoo. Users express optimism about the potential improvement in hair density.

A 25-year-old shared their 3-month progress using a combination of 1mg finasteride and 5% minoxidil for hair loss. The images show noticeable improvement in hair density.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

The user saw hair improvement with minoxidil, finasteride, and a red light cap, noting better results after adding finasteride and stressing routine consistency.

A 29-year-old reports positive hair recovery after 7 months using liposomal topical finasteride and minoxidil, low-level light therapy, and vitamins, following a 3600 graft DHI procedure. They experienced no side effects from the topical treatment, unlike with oral finasteride.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.

A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.

Different minoxidil formulations affect hair growth and side effects. Higher propylene glycol and pH levels improve effectiveness but can cause scalp irritation.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user has been using topical minoxidil (5%) for two years and kx826/pyrilutamide for one year, after experiencing side effects from finasteride. They report positive results from the combination of minoxidil and kx826 in combating hair loss.

The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.

The user is considering getting blood work to investigate the cause of ongoing hair loss despite using finasteride and dutasteride. Others suggest that while blood tests can provide useful health information, they may not change the hair treatment outcome.

The user is treating hair loss with topical Minoxidil, Finasteride, RU58841, microneedling, and Ketoconazole. For grey hair, they use L-Cysteine, L-Methionine, and PABA, and have noticed some re-pigmentation.

A 22-year-old is using a hair loss treatment protocol including dutasteride, microneedling, 10% minoxidil, 0.1% finasteride topical, a healthy diet, and a hair multivitamin. Users discuss the effectiveness of microneedling and the intensity of the treatment.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.